Elanco's Sub-3x Quarter: The Leverage Milestone Arrives, and So Do the Questions
Debt paydown and 300bps of gross margin expansion land the deleveraging story — but Costco exits, the Zenrelia label is deflated, and Quattro's share gains cool into autumn
ELAN · Earnings Call · 2026-11-06
The quarter the deleveraging story needed
For two years Elanco's pitch has been the same three words — growth, innovation, cash — with the implicit promise that the first two would eventually show up in the third. Fiscal Q3 2026 is the first quarter where all three arrived on the same page. Revenue of $1.265 billion grew 11% reported and 9% organic constant currency, split cleanly between 5% volume and 4% price. Adjusted EBITDA of $243 million rose 23%, adjusted EPS of $0.27 rose 42%, and gross margin did the heaviest lifting: “Adjusted gross margin expanded to 56.1% this quarter. Representing a 300 basis point increase over the prior year.” — Robert VanHimbergen, Chief Financial Officer · 2026-11-06 That is not mix-and-hope; it is pricing, a favorable pet/ruminant product mix, and the Elanco Ascend cost program showing up in conversion cost. The balance sheet is where the story becomes hard to argue with. Elanco paid down $216 million of gross debt in the quarter, $317 million year to date, and crossed its own milestone at 2.9x net leverage — a level management had previously framed as the gateway to real capital-allocation flexibility. Effective net cash stood at -$3.3 billion at the last filed quarter, up 8% year over year and $2.5 billion better than four years ago, and free cash flow reached $224 million in the June quarter alone, tracking toward the $1 billion cumulative target by 2028. Here is the catch: none of this is discovery. The tape shows the stock up 108% over a 35-week stretch before going flat for the last 90 days, and price to revenue has already re-rated to 2.4x from about 1.6x a year earlier. Q3 was not a rescue. It was a validation test, and Elanco passed it.The incumbent just confirmed the share shift
What makes the quarter more than arithmetic is that a competitor corroborated it in the same week. Speaking to the US broad-spectrum parasiticide market, Jeff Simmons laid out the share transfer in unusually granular terms:On the derm side the JAK market tells a similar story: Zenrelia reached roughly 19,000 US clinics — about two-thirds of the base — adding 400 to 500 clinics a month, with average sales per clinic up 8% sequentially even as a new entrant arrived. The kicker is that the reporting calendar handed Elanco a rare gift: an incumbent described a challenging competitive dynamic and an overall decline in share loss — a competitor's own vocabulary for what Elanco is doing to it. That is the cleanest third-party confirmation on this call. Which is exactly why the pushback matters. Glen Santangelo of Barclays asked the question the buy side is actually debating — whether Elanco is mid-way through a peak share shift — and Umer Raffat of Evercore caught the nuance: if Quattro had banked 7-9 points of share by the second quarter, a 9-point year-over-year gain in Q3 implies a pause. Simmons did not dodge it: “There is less switching... the growth is actually inside the clinics” — Jeffrey N. Simmons, President and Chief Executive Officer · 2026-11-06. Less switching in the autumn is normal seasonality; but it is also the honest crack in the compounding-share narrative, and it deserves more weight than the slide deck's white-space charts.the top 3 products, Trio, NexGard Plus, and Bravecto, trailing 12 months, have lost 10 points of share. Meanwhile, new innovation, over 70% of that new innovation is from Quattro, has picked up 9 points of share
Three things that went quiet
Costco. In May, CFO Bob VanHimbergen described the new Dollar General and Costco doors as seasonal buys and said “we'd expect reorders again in 2027” — Robert VanHimbergen, Chief Financial Officer · 2026-05-06. In November: “We expect a long term relationship with Costco, but we do expect them to pull back next year.” — Jeffrey N. Simmons, President and Chief Executive Officer · 2026-11-06 The impact is mostly Q1 and supposedly offset by new partners, but a marquee distribution point closing within two quarters of being celebrated is a reminder that omnichannel wins are lumpy. US retail sales were slightly negative in the quarter, with Seresto hit by retailer inventory drawdown. The Zenrelia label. This was positioned for a year as 2027 upside. Now the submission lands at year-end and the ADUFA decision mid-2027, and Simmons pre-emptively disarmed it: “It is not in our guide. It is not expected. We actually see less dependency on this.” — Jeffrey N. Simmons, President and Chief Executive Officer · 2026-11-06 Compare August, when he was still promising to submit “the data as planned to the FDA by no later than the end of the year” — Jeffrey Simmons, President and Chief Executive Officer · 2026-08-05. The timeline has stopped slipping, but a catalyst has been deliberately deflated — sensible risk management, and also a quiet admission that the 2027 algorithm no longer leans on it. Price. Q3's 4% was flattered by lapping launch offers. Guidance is 2%-3% for Q4. In February the CFO was promising acceleration versus 2025's 2%: “I would walk away with expecting price to accelerate from where we were in the last 12 months.” — Robert M. VanHimbergen, Chief Financial Officer · 2026-02-24 It did — and now it normalizes. Simmons' response is a philosophical one, “There can be no doubt we are winning through medical differentiation not discounting” — Jeffrey N. Simmons, President and Chief Executive Officer · 2026-11-06, and it is the fifth consecutive call in which the industry's competitive backdrop is called "responsible" and rival promotions "time bound." When a phrase recurs that reliably, it is less a forecast than a posture.What the survey is really arguing about
The most interesting rhetorical shift is the reframing of veterinary clinic traffic. Elanco has been telling investors to ignore declining vet visits for over a year:That argument is now armed with proprietary research — a survey of more than 1,500 US pet owners, 93% of whom maintained or increased spend — and a new phrase, the lead economic indicator for pet health. Either this is conviction backed by data, or it is a narrative built because industry vet-channel revenue is only up low single digits year to date. Tellingly, US Pet Health lost keyword prominence this quarter while "Total pet health" and "International Pet" rose — the emphasis is shifting to the faster-growing, less-scrutinized geographies. On the farm side, beef shortage economics are a genuine tailwind, offset by newly-flagged regional farm animal cycles in dairy and Chinese swine, and the company flagged that Befrena — however large a 2027 revenue driver — will be gross-margin dilutive as it scales. So the real deliverable is the annual algorithm recommitment: mid-single-digit revenue, high-single-digit EBITDA, low-double-digit EPS through 2028, pre-committed for 2027 before formal guidance in February. On 40x trailing free cash flow, with gross margin running in the high 50s for two straight quarters, that math is defensible — if price holds above 2% and Befrena carries 2027. The bears' question was never whether the innovation is good. It is whether the share gains survive the launch offers. Elanco answered confidently, and hedged once.We believe that vet visits are something we keep our eyes on... we think they're over-indexed for Elanco.